Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL880329 | 0.83 | GAA (0.66) | KDM4ENPC1RAB9ANPSR1PGR | |
| SCHEMBL28587646 | 0.79 | PIM1 (0.53) | KDM4ENPC1CYP1A2RAB9ACYP2C19 | |
| SCHEMBL30386502 | 0.79 | PIM1 (0.53) | KDM4ENPC1CYP1A2RAB9ACYP2C19 | |
| SCHEMBL22663954 | 0.77 | HDAC6 (0.65) | KDM4ENPC1CYP1A2RAB9ACYP2C19 | |
| SCHEMBL25624699 | 0.75 | KDM4E (0.61) | KDM4ENPC1CYP1A2RAB9ACYP2C19 | |
| SCHEMBL20714112 | 0.75 | HDAC6 (0.62) | KDM4ENPC1CYP1A2RAB9ACYP2C19 | |
| SCHEMBL25624873 | 0.75 | NPC1 (0.61) | KDM4ENPC1CYP1A2RAB9ACYP2C19 | |
| SCHEMBL4703660 | 0.75 | ELANE (0.41) | ALDH1A1HSD17B10MEN1KMT2AFAAH | |
| SCHEMBL3476250 | 0.73 | FAAH (0.61) | KDM4ENPC1CYP1A2RAB9ACYP2C19 | |
| SCHEMBL4062301 | 0.73 | NPC1 (0.66) | KDM4ENPC1CYP1A2RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439236-B2 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC (US) | 2008-10-21 | — | — | US | disclosed |
| EP-1219622-B1 | Pharmaceutical compositions for CNS and other disorders | PFIZER PROD INC (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20070099904-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER INC | 2007-05-03 | — | — | US | disclosed |
| US-20050176720-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC | 2005-08-11 | — | — | US | disclosed |
| US-6881734-B2 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC. (US) | 2005-04-19 | — | — | US | disclosed |
| US-6809094-B2 | N-FUSED HETERCYCLO-1,4- OR -1,5- DIAZABICYCLO DERIVATIVES; NICOTINIC RECEPTOR AGONISTS; CENTRAL NERVOUS SYSTEM (CNS) | PFIZER INC | 2004-10-26 | — | — | US | disclosed |
| US-20040204416-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC | 2004-10-14 | — | — | US | disclosed |
| US-20030119837-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC. | 2003-06-26 | — | — | US | disclosed |
| US-20020086871-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | O'NEILL BRIAN THOMAS (US) | 2002-07-04 | — | — | US | disclosed |
| EP-1219622-A2 | Pharmaceutical compositions for CNS and other disorders | Pfizer Products Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176720-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | CHRNA7, CHRNA10, CHRNA5 | KDM4E 4027/4885NPC1 96/4885CYP1A2 769/4885 |
| US-20030119837-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | CHRNA7, CHRNA5, CHRNA10 | KDM4E 4365/4885NPC1 99/4885CYP1A2 729/4885 |
| US-20020086871-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | CHRNA7, CHRNA5, CHRNA10 | KDM4E 4365/4885NPC1 99/4885CYP1A2 729/4885 |
| US-20070099904-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS AND OTHER DISORDERS | C1QBP, BCHE, BDNF | KDM4E 1393/4885NPC1 197/4885CYP1A2 325/4885 |
| US-20040204416-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | CHRNA7, CHRNA5, CHRNA10 | KDM4E 4365/4885NPC1 99/4885CYP1A2 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.